Abstract #1090
Initial experience: combination of MR pharmacokinetic modeling and FDG uptake using simultaneous dynamic contrast enhanced MRI and PET imaging
Nathaniel E. Margolis 1 , Linda Moy 1 , Akshat C. Pujara 1 , Alana Amarosa 1 , Eric E. Sigmund 1 , Christian Geppert 2 , Christopher Glielmi 2 , Melanie Freed 1 , Li Feng 1 , Ricardo Otazo 1 , Amy N. Melsaether 1 , and Sungheon Kim 1
1
Radiology, NYU Langone Medical Center, New
York, New York, United States,
2
Siemens
Medical Solutions, New York, New York, United States
The objective of our study was to assess the feasibility
of using DCE-MRI and PET data for the assessment of
breast cancer MR pharmacokinetics and metabolic
activity. A whole-body integrated 3 T PET/MR scanner was
used to simultaneously acquire DCE-MRI and PET images of
the breast in the prone position. We found trends
between DCE-MRI kinetic model parameters, metastatic
burden, and progesterone receptor status. Our
preliminary results demonstrate the feasibility of using
simultaneous acquired DCE-MRI and PET measures for
better characterization of breast lesions.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
